edaravone has been researched along with Alloxan Diabetes in 12 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment with edaravone (3 and 10 mg/kg) significantly diminished the cerebral infarct, oedema volume and improved functional recovery of neurological deficits." | 5.38 | Edaravone offers neuroprotection in a diabetic stroke model via inhibition of endoplasmic reticulum stress. ( Sharma, SS; Srinivasan, K, 2012) |
| "Edaravone was given once-daily and was intraperitoneally (i." | 1.40 | Edaravone protect against retinal damage in streptozotocin-induced diabetic mice. ( Chen, X; Hang, H; Lin, X; Liu, Q; Liu, X; Xie, P; Xu, Y; Yuan, D; Yuan, S; Zhang, W, 2014) |
| "Treatment with edaravone (3 and 10 mg/kg) significantly diminished the cerebral infarct, oedema volume and improved functional recovery of neurological deficits." | 1.38 | Edaravone offers neuroprotection in a diabetic stroke model via inhibition of endoplasmic reticulum stress. ( Sharma, SS; Srinivasan, K, 2012) |
| "Edaravone or taurine treatment prevented significantly the decreased body, testicular, and epididymal weight induced by diabetes." | 1.38 | Antioxidant treatment with edaravone or taurine ameliorates diabetes-induced testicular dysfunction in the rat. ( Dimitriadis, F; Koukos, S; Saito, M; Satoh, K; Shimizu, S; Sofikitis, N; Takenaka, A; Tsounapi, P, 2012) |
| "Treatment with edaravone prevented partially but significantly the decreased body and penile weight induced by diabetes." | 1.37 | Edaravone ameliorates diabetes-induced dysfunction of NO-induced relaxation in corpus cavernosum smooth muscle in the rat. ( Dimitriadis, F; Inoue, S; Kinoshita, Y; Ohmasa, F; Saito, M; Satoh, K; Shimizu, S; Shomori, K; Tsounapi, P, 2011) |
| "Edaravone is a potent scavenger of hydroxyl radicals and attenuates oxidative damage-related neurodegenerative diseases." | 1.35 | The radical scavenger edaravone counteracts diabetes in multiple low-dose streptozotocin-treated mice. ( Ago, Y; Fukudome, D; Kawasaki, T; Matsuda, M; Matsuda, T, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (25.00) | 29.6817 |
| 2010's | 8 (66.67) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, L | 1 |
| Zeng, YQ | 1 |
| Gu, JH | 1 |
| Song, R | 1 |
| Cang, PH | 1 |
| Xu, YX | 1 |
| Shao, XX | 1 |
| Pu, LJ | 1 |
| Luo, HY | 1 |
| Zhou, XF | 1 |
| Wan, YJ | 1 |
| Hu, L | 1 |
| Wang, XM | 1 |
| Yuan, D | 1 |
| Xu, Y | 1 |
| Hang, H | 1 |
| Liu, X | 1 |
| Chen, X | 1 |
| Xie, P | 1 |
| Yuan, S | 1 |
| Zhang, W | 1 |
| Lin, X | 1 |
| Liu, Q | 1 |
| Ji, L | 1 |
| Liu, Y | 1 |
| Zhang, Y | 1 |
| Chang, W | 1 |
| Gong, J | 1 |
| Wei, S | 1 |
| Li, X | 1 |
| Qin, L | 1 |
| Tsounapi, P | 3 |
| Honda, M | 1 |
| Dimitriadis, F | 3 |
| Shimizu, S | 3 |
| Shiomi, T | 1 |
| Hikita, K | 1 |
| Saito, M | 3 |
| Tomita, S | 1 |
| Sofikitis, N | 2 |
| Takenaka, A | 2 |
| Nagatani, S | 1 |
| Sudo, T | 1 |
| Murakami, Y | 1 |
| Uemura, K | 1 |
| Hiyama, E | 1 |
| Sueda, T | 1 |
| Ohmasa, F | 1 |
| Inoue, S | 1 |
| Shomori, K | 1 |
| Kinoshita, Y | 1 |
| Satoh, K | 2 |
| Srinivasan, K | 1 |
| Sharma, SS | 3 |
| Koukos, S | 1 |
| Saini, AK | 2 |
| Patel, RJ | 1 |
| H S, AK | 1 |
| Kumar H S, A | 1 |
| Fukudome, D | 1 |
| Matsuda, M | 1 |
| Kawasaki, T | 1 |
| Ago, Y | 1 |
| Matsuda, T | 1 |
12 other studies available for edaravone and Alloxan Diabetes
| Article | Year |
|---|---|
Novel oral edaravone attenuates diastolic dysfunction of diabetic cardiomyopathy by activating the Nrf2 signaling pathway.
Topics: Animals; Apoptosis; Diabetes Mellitus, Experimental; Diabetic Cardiomyopathies; Edaravone; NF-E2-Rel | 2022 |
Edaravone protects from retinal injury through NF-κB in diabetic rats.
Topics: Animals; Antioxidants; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Edaravone; Interleukin | 2019 |
Edaravone protect against retinal damage in streptozotocin-induced diabetic mice.
Topics: Animals; Antipyrine; Blotting, Western; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Edara | 2014 |
The antioxidant edaravone prevents cardiac dysfunction by suppressing oxidative stress in type 1 diabetic rats and in high-glucose-induced injured H9c2 cardiomyoblasts.
Topics: Animals; Antioxidants; Antipyrine; Apoptosis; Apoptosis Regulatory Proteins; bcl-2-Associated X Prot | 2016 |
Antioxidant treatment ameliorates diabetes-induced dysfunction of the vas deferens in a rat model.
Topics: Animals; Antioxidants; Antipyrine; Diabetes Mellitus, Experimental; Edaravone; Male; Malondialdehyde | 2018 |
Edaravone, a free radical scavenger, promotes engraftment of intraportally transplanted islet cells.
Topics: Animals; Antipyrine; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Edaravone; Free Ra | 2011 |
Edaravone ameliorates diabetes-induced dysfunction of NO-induced relaxation in corpus cavernosum smooth muscle in the rat.
Topics: Animals; Antipyrine; Blood Glucose; Cyclic GMP; Diabetes Mellitus, Experimental; Edaravone; Free Rad | 2011 |
Edaravone offers neuroprotection in a diabetic stroke model via inhibition of endoplasmic reticulum stress.
Topics: Animals; Antipyrine; Apoptosis; Caspase 12; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type | 2012 |
Antioxidant treatment with edaravone or taurine ameliorates diabetes-induced testicular dysfunction in the rat.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Animals; Antioxidants; Antipyrine; Deoxyguanosine; Diabetes Complicatio | 2012 |
Edaravone attenuates hydroxyl radical stress and augmented angiotensin II response in diabetic rats.
Topics: Angiotensin II; Animals; Antipyrine; Aorta, Thoracic; Blood Pressure; Catalase; Diabetes Mellitus, E | 2006 |
Preventive and curative effect of edaravone on nerve functions and oxidative stress in experimental diabetic neuropathy.
Topics: Animals; Antipyrine; Catalase; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Edaravone; Fr | 2007 |
The radical scavenger edaravone counteracts diabetes in multiple low-dose streptozotocin-treated mice.
Topics: Animals; Antipyrine; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Edar | 2008 |